• Publications
  • Influence
Multidisciplinary meeting on male breast cancer: summary and research recommendations.
TLDR
The Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens to enhance the understanding of male breast cancer. Expand
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
TLDR
Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. Expand
Projecting individualized absolute invasive breast cancer risk in African American women.
TLDR
A model for projecting absolute risk of invasive breast cancer in African American women was developed and its projections with those from the Breast Cancer Risk Assessment Tool were compared and the CARE model usually gave higher risk estimates for AfricanAmerican women than the breast cancer risk assessment tool. Expand
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
TLDR
Long-term raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer over time to tamoxfene in preventing noninvasive disease, with far less toxicity. Expand
Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors.
TLDR
Low socioeconomic status, speaking a primary language other than English, differences in communication styles, mistrust of research and the medical system, fear, embarrassment, and lack of knowledge about the origin of cancer appear to have a negative impact on clinical cancer research participation rates. Expand
Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings.
TLDR
The primary research recommendation is that the impact of isoflavones on breast tissue needs to be evaluated at the cellular level in women at high risk for breast cancer. Expand
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer.
TLDR
There is significant disparity in pain treatment adequacy, with the odds of undertreatment twice as high for minority patients, and these findings persist over 1 month of follow-up, highlighting the complexity of these problems. Expand
Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
TLDR
A substantial percentage of U.S. women would be eligible for tamoxifen chemoprevention according to FDA criteria, but a much smaller percentage would have an estimated net benefit. Expand
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
TLDR
Raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically significant higher risk of noninvasive breast cancer. Expand
Participation of Minorities in Cancer Research
TLDR
Low socioeconomic status, speaking a primary language other than English, differences in communication styles, mistrust of research and the medical system, fear, embarrassment, and lack of knowledge about the origin of cancer appear to have a negative impact on clinical cancer research participation rates. Expand
...
1
2
3
4
5
...